In HER2-positive disease, pCRs were more frequent in ER-negative (75.8%) than ER-positive (50.0%) cases, while pCR rates in triple-negative breast cancer were similar with and without immunotherapy. This evidence concerns the gene ERBB2 and triple-negative breast carcinoma.